Ignite Creation Date:
2024-05-06 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 2:31 PM
Study NCT ID:
NCT05350943
Status:
UNKNOWN
Last Update Posted:
2022-10-18
First Post:
2022-03-24
Brief Title:
HAIC Combined With Toripalimab and Donafenib for Advanced BTC
Sponsor:
Lu Wang MD PhD
Organization:
Fudan University
Study Overview
Official Title:
Phase II Study to Evaluate the Efficacy and Safety of HAIC Combined With Toripalimab and Donafenib in Patients With Advanced Biliary Tract Cancer
Status:
UNKNOWN
Status Verified Date:
2022-10
Last Known Status:
ENROLLING_BY_INVITATION
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single center single arm phase II prospective study to evaluate the efficacy and safety of Hepatic Arterial Infusion Chemotherapy HAIC combined with PD-1 inhibitor immunotherapy Toripalimab and Tyrosine Kinase Inhibitor Donafenib in patients with advanced biliary tract cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None